Publications by authors named "M Zenatri"
Article Synopsis
- Immune checkpoint inhibitors (ICI) have transformed cancer treatment but can lead to rare and serious neurological side effects, such as chronic intestinal pseudo-obstruction (CIPO).
- CIPO may be linked to T cell infiltration and presents with vague symptoms like nausea and constipation, complicating diagnosis and treatment.
- In three cases treated with vedolizumab after corticosteroids failed, there was minimal improvement, suggesting vedolizumab is not an effective option for ICI-induced CIPO at this time.
Background: Poly(ADP-ribose) polymerase inhibitors (PARPis) improved advanced ovarian cancer treatment. Most patients progress during or following PARPi exposure, however, with concerns about sensitivity of subsequent chemotherapy.
Patients And Methods: In this international cohort study, we evaluated the efficacy of a subsequent chemotherapy following PARPi exposure in high-grade ovarian carcinoma patients.
Background: Chemotherapy (CT) remains a backbone treatment of epithelial ovarian cancer (EOC) inducing persistent peripheral neuropathy (CIPN). Using a dedicated patient-reported outcome tool, this study investigated persistent CIPN and its pharmacogenetic predictors in a cohort of long-term EOC survivors.
Methods: Vivrovaire was a French multicenter cohort of patients with EOC free of disease 3 years after CT completion.
Background: Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG, is a tumor-promoting peptide present in the blood of patients with various cancers that has been shown to have prognostic value. We evaluated the prognostic value of plasma hPG in patients with isocitrate dehydrogenase-wild type glioblastoma after surgery.
View Article and Find Full Text PDF